LOMOTIL (atropine sulfate; diphenoxylate hydrochloride) by Pfizer is clinical pharmacology diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood. Approved for older for: atropine is an anticholinergic agent indicated in adults, older for: cycloplegia () mydriasis () penalization of the healthy eye in the treatment of amblyopia () 1. First approved in 1961.
Drug data last refreshed 12h ago · AI intelligence enriched 5d ago
Lomotil is an oral antidiarrheal combination of diphenoxylate hydrochloride and atropine sulfate approved since 1961. Diphenoxylate acts on circular smooth muscle of the bowel to increase segmentation and prolong gastrointestinal transit time, while atropine provides anticholinergic activity. It is indicated for symptomatic relief of diarrhea in adults.
Legacy product with declining claims volume and no active brand investment signals; brand team likely in maintenance mode with minimal headcount expansion.
CLINICAL PHARMACOLOGY Diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood. After a 5-mg oral dose of carbon-14 labeled diphenoxylate hydrochloride in ethanolic solution…
Worked on LOMOTIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCareer opportunities on Lomotil are limited and focused on legacy product management, compliance, and market maintenance rather than growth. Professionals joining this franchise should expect stable but non-expansive roles, with limited visibility and smaller team structures compared to growth-stage products.